Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.30 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398012 | 1.00 | PTPN1 (0.32) | PTPN1HSP90AB1CASRL3MBTL1ABCB1 | |
| SCHEMBL13934755 | 0.90 | MAPT (0.35) | L3MBTL1 | |
| SCHEMBL12717744 | 0.90 | MAPT (0.35) | L3MBTL1 | |
| SCHEMBL13934756 | 0.88 | ABCB1 (0.34) | ABCB1 | |
| SCHEMBL4451943 | 0.86 | ABCB1 (0.34) | L3MBTL1ABCB1 | |
| SCHEMBL4447911 | 0.86 | ABCB1 (0.34) | L3MBTL1ABCB1 | |
| SCHEMBL1398010 | 0.86 | ABCB1 (0.34) | L3MBTL1ABCB1 | |
| SCHEMBL4455714 | 0.86 | ABCB1 (0.34) | L3MBTL1ABCB1 | |
| SCHEMBL1398009 | 0.86 | ABCB1 (0.34) | L3MBTL1ABCB1 | |
| SCHEMBL4448184 | 0.86 | ABCB1 (0.34) | L3MBTL1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928255-B2 | Intermediates for the preparation of lipoxin A4 analogs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-19 | — | — | US | claimed |
| US-20070037864-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | claimed |
| EP-2288414-A1 | ANHYDROUS AND HYDRATE FORMS OF CRYSTALLINE 2- ( (2S, 3R, 4E, 6E, 1OE, 12S) -13- (4-FLUOROPHENOXY) -2,3, 12- (TRIHYDROXYTRIDECA-4, 6, 10-TRIEN-8-YNYL) OXY) ACETIC ACID | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009140984-A1 | ANHYDROUS AND HYDRATE FORMS OF CRYSTALLINE 2- ( (2S, 3R, 4E, 6E, 1OE, 12S) -13- (4-FLUOROPHENOXY) -2,3, 12- (TRIHYDROXYTRIDECA-4, 6, 10-TRIEN-8-YNYL) OXY) ACETIC ACID | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | WO | disclosed |
| US-20090036530-A1 | Crystalline acid of lipoxin A4 analogs and method of making | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20080182901-A1 | Crystalline acid of lipoxin A4 analogs and method of making | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036530-A1 | Crystalline acid of lipoxin A4 analogs and method of making | LTA4H, LTB4R2, ALOX5 | PTPN1 2705/4885HSP90AB1 1948/4885CASR 2617/4885 |
| US-20070037864-A1 | Intermediates for the preparation of lipoxin A4 analogs | LTB4R, LTB4R2, LTA4H | PTPN1 3444/4885HSP90AB1 4107/4885CASR 2583/4885 |
| US-20080182901-A1 | Crystalline acid of lipoxin A4 analogs and method of making | LTA4H, LTB4R2, ALOX5 | PTPN1 2705/4885HSP90AB1 1948/4885CASR 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.